B+
Bull case
0%
Probability
Target price
$90.00
+22.9% vs current
IFF
International Flavors FragrancesBNYSE / Materials
Last Price
At close
2026-06-02
AI scenario view
RankAlpha Sentiment CodexPost-earnings T+3Most likely
B
Base case
1%
Probability
Target price
$80.00
+9.2% vs current
B-
Bear case
0%
Probability
Target price
$69.00
-5.8% vs current
AI sentiment snapshot
Latest data as of 2026-05-08
Recent news sentiment (30D)
+20.1
Positive
Company
-
Unavailable
Macro
+20.1
Positive
Pulse
+16.6
Positive
Sentiment proxy
+57.3
Score
AI commentary
Primary evidence improved after the May 5, 2026 earnings release, but this remains a T+3 monitoring view rather than a fully de-risked thesis. The packet confirms company-reported Q1 execution, reaffirmed guidance and relevant SEC filings, while broad analyst revision evidence and a well-sourced post-print price-reaction read are unavailable. Tone is cautiously constructive, with confidence limited by execution, portfolio-process and legal-overhang risks.
RankAlpha Sentiment Codex - 2026-05-08
Open post-earnings memoEvidence flagged
memo remains a monitoring view with limited forward evidence and should not be standard-conviction
Impact
tentative
Confidence
-
AI events
2026-06-30catalystQ1 execution and reaffirmed guidance support a cautious post-print resetMedium impact
Q1 2026 results showed broad volume growth across all four segments, comparable currency-neutral sales up 3%, comparable currency-neutral adjusted EBITDA up 8%, free cash flow of $92 million, and full-year 2026 guidance was reaffirmed at $10.5 billion-$10.8 billion of sales and $2.05 billion-$2.15 billion of adjusted EBITDA [#8-K-2026-05-05][#10-Q-2026-05-05].
2026-09-30eventFood Ingredients portfolio process remains the clearest discrete value leverHigh impact
Management said it is running a disciplined sale process for the Food Ingredients business, while guidance reflects the Soy Crush, Concentrates and Lecithin divestiture closing on March 2, 2026, one month earlier than previously expected; a clearer transaction update could change sum-of-the-parts expectations, but timing and proceeds remain unconfirmed [#8-K-2026-05-05][#10-Q-2026-05-05].
2026-12-31catalystVolume-led margin recovery and leverage control need more quarters of proofHigh impact
Taste, Health & Biosciences and Food Ingredients posted comparable currency-neutral EBITDA growth, while net debt to credit-adjusted EBITDA was 2.53x and the company remained in covenant compliance; sustained productivity and cash generation would improve confidence that the turnaround is durable, but one quarter is not enough to de-risk execution [#10-Q-2026-05-05].
Recommendation
N/A
No formal recommendation provided.
As of 2026-05-08 • Updated nightlySource: Internal modelMethodology